ArticleThe journal of obstetrics and gynaecology research2026
Impact of Sarcopenia and Pretreatment Skeletal Muscle Loss on Survival in Endometrial Cancer Patients Treated With Immune Checkpoint Inhibitors.
Article in The journal of obstetrics and gynaecology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimSarcopenia and cancer-related muscle wasting may affect the efficacy of immune checkpoint inhibitors (ICIs). However, their prognostic significance in endometrial cancer (EC), particularly concerning skeletal muscle status at ICI initiation and pretreatment muscle change, remains unclear. We evaluated the impact of sarcopenia at ICI initiation and pre-ICI skeletal muscle dynamics on clinical outcomes in EC.
methodsWe retrospectively analyzed 20 EC patients treated with ICIs between May 2019 and December 2024. Skeletal muscle index (SMI) was quantified using abdominal CT at the L3 level within 2 months before ICI initiation. Sarcopenia was defined as SMI < 38.5 cm
resultsTen patients (50%) were sarcopenic at ICI initiation and showed a trend toward poorer progression-free survival (PFS) and overall survival (OS). Pre-treatment muscle loss occurred in two-thirds of patients. Patients with decreased SMI had significantly worse OS (HR 3.64, 95% CI 1.11-11.94). In subgroup analysis, SMI decline was frequent among sarcopenic patients but did not stratify survival. In contrast, among nonsarcopenic patients, greater SMI loss was associated with poorer survival, and each 1-unit decrease in SMI significantly worsened OS (HR 1.64, 95% CI 1.05-2.63).
conclusionsSarcopenia at ICI initiation and pretreatment skeletal muscle loss are potential predictors of poor prognosis in EC. Evaluating baseline muscle mass and its trajectory may improve risk stratification and help identify patients at higher risk of ICI resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.